• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    4/2/24 4:31:04 PM ET
    $ACOR
    $AIH
    $BNOX
    $CUTR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities
    Health Care
    Get the next $ACOR alert in real time by email

    Gainers

    • OneMedNet (NASDAQ:ONMD) shares moved upwards by 75.9% to $1.39 during Tuesday's after-market session. The market value of their outstanding shares is at $44.8 million.
    • Aesthetic Medical Intl (NASDAQ:AIH) shares rose 43.48% to $0.49. The market value of their outstanding shares is at $23.1 million.
    • Sight Sciences (NASDAQ:SGHT) shares rose 20.77% to $6.57. The market value of their outstanding shares is at $325.5 million.
    • Inspire Veterinary (NASDAQ:IVP) stock increased by 16.59% to $0.05. The market value of their outstanding shares is at $1.7 million.
    • GlycoMimetics (NASDAQ:GLYC) stock rose 6.41% to $3.15. The market value of their outstanding shares is at $203.0 million. As per the news, the Q4 earnings report came out 4 days ago.
    • Bionomics (NASDAQ:BNOX) stock rose 6.01% to $1.05. The market value of their outstanding shares is at $11.2 million.

    Losers

    • Enveric Biosciences (NASDAQ:ENVB) stock decreased by 14.1% to $0.98 during Tuesday's after-market session. The market value of their outstanding shares is at $7.1 million.
    • Acorda Therapeutics (NASDAQ:ACOR) stock fell 12.0% to $2.2. The market value of their outstanding shares is at $2.7 million. As per the news, the Q4 earnings report came out yesterday.
    • Imunon (NASDAQ:IMNN) shares declined by 7.43% to $1.62. The market value of their outstanding shares is at $15.2 million. As per the press release, Q4 earnings came out 3 days ago.
    • Mira Pharmaceuticals (NASDAQ:MIRA) shares decreased by 6.55% to $1.0. The market value of their outstanding shares is at $14.7 million. As per the press release, Q4 earnings came out yesterday.
    • Cyclo Therapeutics (NASDAQ:CYTH) shares fell 6.17% to $1.37. The market value of their outstanding shares is at $39.3 million.
    • Cutera (NASDAQ:CUTR) shares decreased by 4.9% to $1.36. The market value of their outstanding shares is at $27.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACOR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACOR
    $AIH
    $BNOX
    $CUTR

    CompanyDatePrice TargetRatingAnalyst
    Sight Sciences Inc.
    $SGHT
    1/5/2026$9.00Neutral → Overweight
    Piper Sandler
    Sight Sciences Inc.
    $SGHT
    8/8/2025$5.00Hold → Buy
    Lake Street
    GlycoMimetics Inc.
    $GLYC
    3/21/2025Overweight
    Cantor Fitzgerald
    Sight Sciences Inc.
    $SGHT
    12/6/2024$5.50Buy
    UBS
    Sight Sciences Inc.
    $SGHT
    11/4/2024$10.00 → $5.00Buy → Hold
    Lake Street
    Sight Sciences Inc.
    $SGHT
    8/21/2024$10.00Buy
    Lake Street
    GlycoMimetics Inc.
    $GLYC
    7/26/2024Buy → Hold
    TD Cowen
    Cutera Inc.
    $CUTR
    3/22/2024Underperform → Mkt Perform
    William Blair
    More analyst ratings

    $ACOR
    $AIH
    $BNOX
    $CUTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Encrantz Staffan bought $115,963 worth of shares (13,958 units at $8.31), increasing direct ownership by 1% to 1,391,922 units (SEC Form 4)

    4 - Sight Sciences, Inc. (0001531177) (Issuer)

    12/18/25 6:10:08 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Chief Medical Officer Yu Jeffrey converted options into 2,307,549 shares, bought $959,586 worth of shares (2,010,479 units at $0.48) and was granted 245,000 shares, increasing direct ownership by 165% to 7,326,223 units (SEC Form 4)

    4 - OneMedNet Corp (0001849380) (Issuer)

    11/26/25 9:56:08 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Medical Officer Yu Jeffrey bought $8,929 worth of shares (9,540 units at $0.94) and was granted 230,769 shares, increasing direct ownership by 10% to 2,763,195 units (SEC Form 4)

    4 - OneMedNet Corp (0001849380) (Issuer)

    11/26/25 9:55:32 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ACOR
    $AIH
    $BNOX
    $CUTR
    SEC Filings

    View All

    SEC Form 10-K filed by MIRA Pharmaceuticals Inc.

    10-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)

    3/31/26 2:02:37 PM ET
    $MIRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Imunon Inc.

    10-K - Imunon, Inc. (0000749647) (Filer)

    3/31/26 8:50:51 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Imunon Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Imunon, Inc. (0000749647) (Filer)

    3/31/26 8:05:35 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $AIH
    $BNOX
    $CUTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Technology Officer Badawi David exercised 21,270 shares at a strike of $0.23, increasing direct ownership by 1% to 1,998,458 units (SEC Form 4)

    4 - Sight Sciences, Inc. (0001531177) (Issuer)

    2/23/26 4:28:55 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Aminov Erez was granted 125,000 shares, exercised 613,595 shares at a strike of $0.96 and sold $1,294,685 worth of shares (613,595 units at $2.11), increasing direct ownership by 4% to 3,592,666 units (SEC Form 5)

    5 - MIRA PHARMACEUTICALS, INC. (0001904286) (Issuer)

    2/17/26 8:30:02 PM ET
    $MIRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Technology Officer Badawi David was granted 64,915 shares, increasing direct ownership by 3% to 1,977,188 units (SEC Form 4)

    4 - Sight Sciences, Inc. (0001531177) (Issuer)

    2/5/26 4:49:56 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $ACOR
    $AIH
    $BNOX
    $CUTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates

    Patent provides added depth to Enveric's EVM301 intellectual property portfolio of potential neuroplastogenic molecules for non-hallucinogenic treatment of neuropsychiatric conditions Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that on March 17, 2026, it received U.S. Patent No. 12,577,232 ("the'232 patent") from the United States Patent and Trademark Office (USPTO) pertaining to its EVM301 Series of molecules. The EVM301 Series includes lead candidate, EB-003, being developed as potential treatments for mental health d

    3/31/26 8:00:00 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study

    IMNN-001 is the first frontline immunotherapy to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with advanced ovarian cancer Final Phase 2 clinical data show continued median overall survival improvement with IMNN-001 Enrollment in the OVATION 3 Study, IMUNON's Phase 3 pivotal trial for IMNN-001, remains ahead of plan supported by continued strong interest from principal investigators and the medical community Company to hold conference call today at 11:00 a.m. EDT LAWRENCEVILLE, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunother

    3/31/26 8:00:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sight Sciences to Present at the 25th Annual Needham Healthcare Conference on April 13th

    MENLO PARK, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced plans to present at the 25th Annual Needham Healthcare Conference being held virtually. Sight Sciences' management is scheduled to present on Monday, April 13, 2026, at 11:15 am PT / 2:15 pm ET. Interested parties may access a live and archived webcast of the fireside chat on the "Investors" section of the Company's website at https://investors.sightsciences.com/. About Sight Scienc

    3/30/26 4:05:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $ACOR
    $AIH
    $BNOX
    $CUTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sight Sciences upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Sight Sciences from Neutral to Overweight and set a new price target of $9.00

    1/5/26 8:36:47 AM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Sight Sciences upgraded by Lake Street with a new price target

    Lake Street upgraded Sight Sciences from Hold to Buy and set a new price target of $5.00

    8/8/25 8:25:35 AM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Cantor Fitzgerald initiated coverage on GlycoMimetics

    Cantor Fitzgerald initiated coverage of GlycoMimetics with a rating of Overweight

    3/21/25 8:14:54 AM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $AIH
    $BNOX
    $CUTR
    Leadership Updates

    Live Leadership Updates

    View All

    ENvue Medical Appoints Veteran Healthcare-Industry Executive, David Johnson, as Chairman

    ENvue Medical, Inc. (NASDAQ:FEED) ("ENvue" or the "Company"), a medical technology company specializing in non-invasive therapeutic systems, today announced the appointment of David Johnson as Chairman of the Board. Mr. Johnson will work alongside CEO, Doron Besser, and the existing leadership team. David Johnson, newly appointed Chairman of ENvue, stated, "We believe ENvue is at the forefront of advanced feeding-tube placement technology, which has been validated in the market and extensively used in the clinic across 38 hospitals in the US. In my opinion, the Company's unique feeding tube placement system that utilizes advanced methods of navigation, integrated sensors and body mapping h

    12/15/25 9:00:00 AM ET
    $ENVB
    $FEED
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    Sight Sciences Appoints Ali Bauerlein as Chief Operating Officer and Jim Rodberg as Chief Financial Officer

    MENLO PARK, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of Alison (Ali) Bauerlein as its Chief Operating Officer (COO) and James (Jim) Rodberg as its Chief Financial Officer (CFO), effective November 5, 2025. "We are very excited to promote both Ali and Jim into new roles at Sight Sciences as we continue to elevate our market leadership position in MIGS and begin to scale the reimbursed interventional dry eye category. We believe the many contribu

    11/6/25 4:04:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Crescent Biopharma Appoints David Lubner to Board of Directors

    Industry Veteran Brings 30 Years of Experience in Finance, Strategy and Operations WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company developing novel precision-engineered molecules targeting validated biology to advance care for patients with solid tumors, today announced the appointment of David Lubner to its board of directors.   "David brings extensive experience in senior executive and board roles with particular expertise in finance, operations and corporate strategy," said Peter Harwin, chairman of Crescent's Board of Directors. "His contributions to Crescent will be instrumental as we continue to grow, advance

    4/28/25 7:30:00 AM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $AIH
    $BNOX
    $CUTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by GlycoMimetics Inc.

    SC 13G - GLYCOMIMETICS INC (0001253689) (Subject)

    11/27/24 2:22:44 PM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Imunon Inc.

    SC 13G - Imunon, Inc. (0000749647) (Subject)

    11/14/24 5:37:34 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Enveric Biosciences Inc.

    SC 13G/A - Enveric Biosciences, Inc. (0000890821) (Subject)

    11/14/24 4:03:47 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $AIH
    $BNOX
    $CUTR
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at GlycoMimetics Inc. on Jun 20 Indicate?

    Recently, on June 20, 2024, an insider purchase was made at GlycoMimetics Inc., grabbing the attention of investors. According to the SEC Form 4 filing, SVP Finance, CFO Hahn Brian M. bought $4,335 worth of shares (17,500 units at $0.25), boosting direct ownership by 33% to 70,643 units. Insider transactions are closely monitored by investors as they can provide insights into the company's prospects and the confidence of insiders in the business. Let's delve deeper into the recent insider purchase and analyze any potential patterns or significance in comparison to other insider transactions at GlycoMimetics Inc. In early April 2024, Goldberg Mark Alan was granted 4,584 shares, augmenting di

    6/20/24 6:20:00 PM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $AIH
    $BNOX
    $CUTR
    Financials

    Live finance-specific insights

    View All

    IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026

    LAWRENCEVILLE, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company will host a conference call at 11:00 a.m. EDT on Tuesday, March 31, 2026 to discuss financial results for the year ended December 31, 2025, and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy. The Company is hosting a conference call to review 2025 financial results and provide a business update on March 31, 2026 at 11:00 a.m. EDT. To participate in the call, please dial 800-715-9871 (North America/Toll Free) or 646-307-1

    3/24/26 8:00:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sight Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Initiates Full Year 2026 Financial Guidance

    MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the fourth quarter and full year ended December 31, 2025 and initiated financial guidance for full year 2026.   Recent Financial Highlights Generated fourth quarter 2025 total revenue of $20.4 million, an increase of 7% compared to the same period in the prior year, and full year 2025 total revenue of $77.4 million, a decrease of 3% compared to full year 2

    3/4/26 4:05:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Sight Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

    MENLO PARK, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the fourth quarter and full year ended December 31, 2025, after the market close on Wednesday, March 4, 2026. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast

    2/18/26 4:05:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care